Four things to know:
1. The company’s net sales were $118.1 million, down 2.7 percent from the same period last year.
2. Spinal implant sales fell 6.2 percent to $28.2 million, and biologic sales fell less than 1 percent, to $14.8 million.
3. All areas of Orthofix’s business except global orthopedics saw year-over-year decreases in revenue. Global orthopedics saw a 2 percent increase in revenue year over year..
4. The company saw gross profits of $86.5 million, down 8 percent year over year.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
